{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:40:59Z","timestamp":1790721659647,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00417-021-05283-0","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T04:02:56Z","timestamp":1626062576000},"page":"3665-3673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence"],"prefix":"10.1007","volume":"259","author":[{"given":"Sean D.","family":"Adrean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Chaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash","family":"Pirouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"24","key":"5283_CR1","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358(24):2606\u20132617","journal-title":"N Engl J Med"},{"key":"5283_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. NEJM 355:1419\u20131431","journal-title":"NEJM"},{"issue":"1","key":"5283_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57-65.e5","journal-title":"Ophthalmology"},{"issue":"8","key":"5283_CR4","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying GS et al (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123(8):1751\u20131761","journal-title":"Ophthalmology"},{"issue":"11","key":"5283_CR5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292\u20132299","journal-title":"Ophthalmology"},{"issue":"7","key":"5283_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Ramkumar H et al (2018) Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol. Ophthalmology 125(7):1047\u20131053","journal-title":"Ophthalmology"},{"issue":"9","key":"5283_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/IAE.0000000000002668","volume":"40","author":"MR Starr","year":"2020","unstructured":"Starr MR, Kung FF, Mejia CA et al (2020) Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina 40(9):1665\u20131672","journal-title":"Retina"},{"issue":"12","key":"5283_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537\u20132548","journal-title":"Ophthalmology"},{"issue":"5","key":"5283_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM et al (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120(5):1046\u201356","journal-title":"Ophthalmology"},{"issue":"7","key":"5283_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"CATT Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388\u20131398","journal-title":"Ophthalmology"},{"issue":"5","key":"5283_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001282","volume":"37","author":"WM Haddad","year":"2017","unstructured":"Haddad WM, Minous FL, Legeai J et al (2017) Long-term outcomes and incidence of recurrence of neovascularization in treated exudative age-related macular degeneration. Retina 37(5):951\u2013961","journal-title":"Retina"},{"key":"5283_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2015","unstructured":"Arevalo JF, Lasave AF, Wu L et al (2015) Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group. Retina 36:859\u2013867","journal-title":"Retina"},{"issue":"9900","key":"5283_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258\u20131267","journal-title":"Lancet"},{"issue":"3","key":"5283_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","volume":"2","author":"SD Adrean","year":"2018","unstructured":"Adrean SD, Chaili S, Grant S et al (2018) Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a treat\u2013extend\u2013stop protocol. Ophthalmol Retina 2(3):225\u2013230","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"5283_CR15","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD et al (2014) Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121(11):2181\u201392","journal-title":"Ophthalmology"},{"issue":"4","key":"5283_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","volume":"122","author":"MC Peden","year":"2015","unstructured":"Peden MC, Su\u00f1er IJ, Hammer ME et al (2015) Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 122(4):803\u2013808","journal-title":"Ophthalmology"},{"key":"5283_CR17","doi-asserted-by":"publisher","first-page":"4263017","DOI":"10.1155\/2017\/4263017","volume":"2017","author":"AC Pedrosa","year":"2017","unstructured":"Pedrosa AC, Sousa T, Pinheiro-Costa J et al (2017) Treatment of neovascular age-related macular degeneration with anti-VEGF agents: predictive factors of long-term visual outcomes. J Ophthalmol 2017:4263017. https:\/\/doi.org\/10.1155\/2017\/4263017","journal-title":"J Ophthalmol"},{"issue":"2","key":"5283_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/IAE.0000000000000374","volume":"35","author":"L Xu","year":"2015","unstructured":"Xu L, Mrejen S, Jung JJ et al (2015) Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 35(2):176\u2013186. https:\/\/doi.org\/10.1097\/IAE.0000000000000374","journal-title":"Retina"},{"issue":"4","key":"5283_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.oret.2017.07.010","volume":"2","author":"MR Munk","year":"2018","unstructured":"Munk MR, Arendt P, Yu S, Ceklic L, Huf W, Ebneter A, Wolf S, Zinkernagel MS (2018) The impact of the vitreomacular interface in neovascular age-related macular degeneration in a treat-and-extend regimen with exit strategy. Ophthalmol Retina 2(4):288\u2013294. https:\/\/doi.org\/10.1016\/j.oret.2017.07.010","journal-title":"Ophthalmol Retina"},{"issue":"10","key":"5283_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","volume":"100","author":"K Hatz","year":"2016","unstructured":"Hatz K, Pr\u00fcnte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100(10):1341\u20131345","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"5283_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00417-013-2338-z","volume":"251","author":"SY Cohen","year":"2013","unstructured":"Cohen SY, Dubois L, Ayrault S et al (2013) Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefes Arch Clin Exp Ophthalmol 251(11):2499\u20132503","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5283_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/OPTH.S133332","volume":"11","author":"N Miyamoto","year":"2017","unstructured":"Miyamoto N, Mandai M, Kojima H et al (2017) Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning. Clin Ophthalmol 11:809\u2013816","journal-title":"Clin Ophthalmol"},{"key":"5283_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000442782","volume":"56","author":"B Lumbroso","year":"2016","unstructured":"Lumbroso B, Rispoli M, Savastano MC et al (2016) Optical coherence tomography angiography study of choroidal neovascularization early response after treatment. Dev Ophthalmol 56:77\u201385","journal-title":"Dev Ophthalmol"},{"issue":"9","key":"5283_CR24","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D et al (2015) Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 122(9):1837\u20131845","journal-title":"Ophthalmology"},{"issue":"5","key":"5283_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S et al (2015) Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159(5):915\u201324.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.032","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"5283_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald JE, Pistilli M, Daniel E et al (2017) Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology 124(1):97\u2013104. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.012","journal-title":"Ophthalmology"},{"issue":"11","key":"5283_CR27","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00417-017-3762-2","volume":"255","author":"P Parvin","year":"2017","unstructured":"Parvin P, Zola M, Dirani A et al (2017) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. Graefes Arch Clin Exp Ophthalmol 255(11):2127\u20132134. https:\/\/doi.org\/10.1007\/s00417-017-3762-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"5283_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/ICU.0000000000000763","volume":"32","author":"AJ Richard","year":"2021","unstructured":"Richard AJ, Duker JS, Reichel E (2021) Geographic atrophy: where we are now and where we are going. Curr Opin Ophthalmol 32(3):247\u2013252. https:\/\/doi.org\/10.1097\/ICU.0000000000000763","journal-title":"Curr Opin Ophthalmol"},{"key":"5283_CR29","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westneskow PD, Bravo S et al (2012) Targeted deletion of VEGF-A in adult mice induces vision loss. J Clin Invest 122:4213\u20134217","journal-title":"J Clin Invest"},{"issue":"6","key":"5283_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B et al (2018) Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 125(6):878\u2013886. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026","journal-title":"Ophthalmology"},{"issue":"8","key":"5283_CR31","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","volume":"94","author":"MR Munk","year":"2016","unstructured":"Munk MR, Ceklic L, Ebneter A et al (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94(8):e757\u2013e764. https:\/\/doi.org\/10.1111\/aos.13157","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"5283_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oret.2016.09.005","volume":"1","author":"AT Thavikulwat","year":"2017","unstructured":"Thavikulwat AT, Jacobs-El N, Kim JS et al (2017) Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina 1(1):34\u201341. https:\/\/doi.org\/10.1016\/j.oret.2016.09.005","journal-title":"Ophthalmol Retina"},{"key":"5283_CR33","first-page":"311","volume":"107","author":"PK Kaiser","year":"2009","unstructured":"Kaiser PK (2009) Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc 107:311\u2013324","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05283-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05283-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T09:18:08Z","timestamp":1636708688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05283-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5283"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05283-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (IRB# 2017\u20130023-RCOC, IRB Co, Buena Park, CA, USA) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not needed as patient identifying information was removed and results were aggregated for reporting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Adrean reports grants from Genentech, grants from Ohr, grants from Regeneron, grants from SciFluor, grants from Ophthotech, grants from Allergan, outside the submitted work. Dr. Chaili has no conflicts to report. Dr. Pirouz reports grants from Regeneron, grants from Ophthotech, grants from Allergan, outside the submitted work. Dr. Grant reports grants from Genentech, grants from Ohr, grants from Regeneron, grants from SciFluor, grants from Ophthotech, grants from Allergan, outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}